Genetics
Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response
17/12/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). […]
Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
17/12/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan […]
Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
18/11/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in […]
Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
18/06/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation in the European Association for Cancer […]
Asuragen to Present at 2020 European Society of Human Genetics (ESHG) Virtual Conference
Corporate satellite presentation and scientific posters highlight new AmplideX® testing kits 02/06/2020 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing […]
Asuragen Develops Armored RNA Quant® SARS-CoV-2 Control
New reference material aims to facilitate and expedite global efforts to detect the novel coronavirus 16/03/2020 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc. has developed an Armored RNA Quant® […]
Terrace Global Announces Genetics Supply Agreement With Apollo Green for Acquisition of Genetics and Importation Into the European Union
Highlights: Terrace Global enters into exclusive genetics supply agreement with Apollo Green, a leading Canadian licensed producer of medical cannabis with a focus on specialized genetics and plantlet sales. Acquires […]
Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019
11/12/2019 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology […]
Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies
19/11/2019 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science […]
Asuragen Launches Assay to Aid in the Diagnosis of Myotonic Dystrophy Type I (DM1)
The AmplideX® DM1 Dx Kit is now available in countries accepting the CE mark 04/12/2018 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products […]
Asuragen Expands Oncology Portfolio with CE Marking and Launch of QuantideX® NGS DNA Hotspot 21 Kit
The panel accurately and sensitively detects over 1600 variants of clinical significance 05/09/2018 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy to use […]
Asuragen to Launch the AmplideX® PCR/CE DMPK Kit and Present Growing Genetic Testing Portfolio at 2018 European Society of Human Genetics (ESHG) Conference
The AmplideX DMPK Kit is the first of several new genetics products in 2018 22/05/2018 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy […]
Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer
17/01/2018 — AUSTIN, Texas — (BUSINESS WIRE) Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests […]
Toshiba Pushes Quantum Key Distribution Speed Beyond 10Mbps
— Achieves highest speed ever recorded in unbreakable, secure communications — 15/09/2017 — TOKYO — (BUSINESS WIRE) Toshiba Corporation (TOKYO:6502) and Toshiba Research Europe Limited’s Cambridge Research Laboratory in the […]
IntegenX Applauds the Passage of the Rapid DNA Act of 2017
Amendment of the DNA Identification Act of 1994 is a substantial step forward in making real-time DNA testing of arrestees in the booking environment a reality 21/08/2017 — PLEASANTON, Calif. […]
Swift Biosciences Announces New Industry-Leading Indexed Adapters for Sequencing Larger Numbers of Samples in a Single Run
Revolutionary technology will accelerate utility of gene mapping, biomarker discovery, tumor profiling, and liquid biopsy analysis 03/08/2017 — ANN ARBOR, Mich. — (BUSINESS WIRE) Swift Biosciences, a leading provider of […]
IntegenX Announces a New RapidHIT® ID Cartridge System, Expanding the Utility of the Easiest to Use Rapid DNA System
Allows laboratories to generate forensic DNA profiles from extracted and quantified DNA samples in 90 minutes Several crime scene samples tested with the new system uploaded into CODIS, including DNA […]
LFB S.A. Announced Today the Acceptance by U.S. Food and Drug Administration of the Filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)
06/01/2017 — LES ULIS, France — (BUSINESS WIRE) LFB S.A., announced that its Biologic License Application (BLA), requesting marketing approval of Coagulation Factor VIIa (Recombinant) as a treatment for congenital […]
Samsung Bioepis’ RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as SB2 – for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis and plaque psoriasis. This marks the second regulatory approval for Samsung Bioepis in Korea. The MFDS approved in September 2015 Samsung Bioepis’ BRENZYS®, a biosimilar version of Enbrel® (etanercept), also known as SB4.
Samsung Bioepis Receives Positive CHMP Opinion for the First Etanercept Biosimilar in the European Union
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Benepali® – a biosimilar version of Enbrel® (etanercept), previously known as SB4 – for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque psoriasis. This marks the first time the CHMP has adopted a positive opinion on an etanercept biosimilar.